Mitochondria in Cancer Stem Cells: From an Innocent Bystander to a Central Player in Therapy Resistance.
Sireesha V GarimellaSiri Chandana GampaPankaj ChaturvediPublished in: Stem cells and cloning : advances and applications (2023)
Cancer continues to rank among the world's leading causes of mortality despite advancements in treatment. Cancer stem cells, which can self-renew, are present in low abundance and contribute significantly to tumor recurrence, tumorigenicity, and drug resistance to various therapies. The drug resistance observed in cancer stem cells is attributed to several factors, such as cellular quiescence, dormancy, elevated aldehyde dehydrogenase activity, apoptosis evasion mechanisms, high expression of drug efflux pumps, protective vascular niche, enhanced DNA damage response, scavenging of reactive oxygen species, hypoxic stability, and stemness-related signaling pathways. Multiple studies have shown that mitochondria play a pivotal role in conferring drug resistance to cancer stem cells, through mitochondrial biogenesis, metabolism, and dynamics. A better understanding of how mitochondria contribute to tumorigenesis, heterogeneity, and drug resistance could lead to the development of innovative cancer treatments.
Keyphrases
- cancer stem cells
- reactive oxygen species
- dna damage response
- cell death
- papillary thyroid
- oxidative stress
- squamous cell
- endoplasmic reticulum
- signaling pathway
- cell cycle arrest
- endoplasmic reticulum stress
- squamous cell carcinoma
- single cell
- risk factors
- epithelial mesenchymal transition
- bone marrow
- young adults
- cardiovascular events
- microbial community
- adverse drug
- combination therapy
- cell therapy